[Treatment of hypercholesterolemia in kidney transplant recipients]

MeSH terms

• Aryl Hydrocarbon Hydroxylases / metabolism
• Cardiovascular Diseases / etiology
• Cardiovascular Diseases / prevention & control*
• Cyclosporine / pharmacology
• Cyclosporine / therapeutic use
• Cytochrome P-450 CYP3A
• Drug Interactions
• Fatty Acids, Monounsaturated / adverse effects
• Fatty Acids, Monounsaturated / pharmacokinetics
• Fatty Acids, Monounsaturated / therapeutic use
• Fluvastatin
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
• Hypercholesterolemia / drug therapy*
• Hypercholesterolemia / etiology
• Immunosuppressive Agents / pharmacology
• Immunosuppressive Agents / therapeutic use
• Indoles / adverse effects
• Indoles / pharmacokinetics
• Indoles / therapeutic use
• Kidney Transplantation / adverse effects*
• Oxidoreductases, N-Demethylating / metabolism
• Primary Prevention
• Risk Factors